{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:15:31Z","timestamp":1740172531660,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Liver function of intensive care patients is routinely monitored by static blood pathology. For specific indications, liver specific cytochrome activity may be measured by the commercially available maximum liver function capacity (LiMAx) test via quantification of the cytochrome P450 1A2 (CYP1A2) dependent C-methacetin metabolism. Sedation with the volatile anesthetic isoflurane was suspected to abrogate the correlation of LiMAx test with global liver function. We hypothesized that isoflurane has a CYP1A2-activity and LiMAx test result decreasing effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this monocentric, observational clinical study previously liver healthy intensive care patients, scheduled to be changed from propofol to isoflurane sedation, were enrolled. LiMAx testing was done before, during and after termination of isoflurane sedation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean LiMAx value decreased during isoflurane sedation. Septic patients (<jats:italic>n<\/jats:italic>\u2009=\u200911) exhibited lower LiMAx values compared to non-septic patients (<jats:italic>n<\/jats:italic>\u2009=\u200911) at all time points. LiMAx values decreased with isoflurane from 140\u2009\u00b1\u200982 to 30\u2009\u00b1\u200934 \u00b5g kg<jats:sup>\u22121<\/jats:sup> h<jats:sup>\u22121<\/jats:sup> in the septic group and from 253\u2009\u00b1\u200992 to 147\u2009\u00b1\u2009131 \u00b5g kg<jats:sup>\u22121<\/jats:sup> h<jats:sup>\u22121<\/jats:sup> in the non-septic group while laboratory markers did not imply significant hepatic impairment. Lactate increased during isoflurane inhalation without clinical consequence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Sepsis and isoflurane have independently demonstrated an effect on reducing the hepatic CYP1A2-activity. A network model was constructed that could explain the mechanism through the influence of isoflurane on hypoxia inducible factor (HIF-1\u03b1) by upregulation of the hypoxia-inducible pathway and the downregulation of CYP1A2-activity via the ligand-inducible pathway. Thus, the increased anaerobic metabolism may result in lactate accumulation. The influence of isoflurane sedation on the validated correlation of global liver function with CYP1A2-activity measured by LiMAx testing needs to be investigated in more detail.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40635-024-00617-8","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T16:02:00Z","timestamp":1712592120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isoflurane, like sepsis, decreases CYP1A2 liver enzyme activity in intensive care patients: a clinical study and network model"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-8382","authenticated-orcid":false,"given":"Thomas","family":"K\u00f6hler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-2986","authenticated-orcid":false,"given":"Elke","family":"Schwier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-1800","authenticated-orcid":false,"given":"Janina","family":"Praxenthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-2877","authenticated-orcid":false,"given":"Carmen","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-5275","authenticated-orcid":false,"given":"G\u00fcnther","family":"Winde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-4124","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Koos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-6885","authenticated-orcid":false,"given":"Dietrich","family":"Henzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/hep.30824","volume":"70","author":"T Horvatits","year":"2019","unstructured":"Horvatits T, Drolz A, Trauner M, Fuhrmann V (2019) Liver injury and failure in critical illness. Hepatology 70:2204\u20132215","journal-title":"Hepatology"},{"key":"617_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","volume":"250","author":"M Stockmann","year":"2009","unstructured":"Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P (2009) Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 250:119\u2013125","journal-title":"Ann Surg"},{"key":"617_CR3","unstructured":"U.S. Food and Drug Administration (2022) Drug development and drug interactions, table of substrates, inhibitors and inducers. In: Editor (ed)^(eds) Book drug development and drug interactions, table of substrates, inhibitors and inducers. City, pp."},{"key":"617_CR4","first-page":"5362514","volume":"2019","author":"C Kirchner","year":"2019","unstructured":"Kirchner C, Sibai J, Schwier E, Henzler D, Eickmeyer C, Winde G, K\u00f6hler T (2019) Dosing of antimycotic treatment in sepsis-induced liver dysfunction by functional liver testing with LiMAx\u00ae. Case Rep Crit Care 2019:5362514","journal-title":"Case Rep Crit Care"},{"key":"617_CR5","doi-asserted-by":"publisher","first-page":"R259","DOI":"10.1186\/cc13089","volume":"17","author":"MF Kaffarnik","year":"2013","unstructured":"Kaffarnik MF, Lock JF, Vetter H, Ahmadi N, Lojewski C, Malinowski M, Neuhaus P, Stockmann M (2013) Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test. Crit Care 17:R259","journal-title":"Crit Care"},{"key":"617_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178237","volume":"12","author":"MF Kaffarnik","year":"2017","unstructured":"Kaffarnik MF, Ahmadi N, Lock JF, Wuensch T, Pratschke J, Stockmann M, Malinowski M (2017) Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test) A prospective study. PLoS ONE 12:e0178237","journal-title":"PLoS ONE"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12871-018-0538-0","volume":"18","author":"M Buechter","year":"2018","unstructured":"Buechter M, Gerken G, Hoyer DP, Bertram S, Theysohn JM, Thodou V, Kahraman A (2018) Liver maximum capacity (LiMAx) test as a helpful prognostic tool in acute liver failure with sepsis: a case report. BMC Anesthesiol 18:71","journal-title":"BMC Anesthesiol"},{"key":"617_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4862","volume":"9","author":"E Schwier","year":"2021","unstructured":"Schwier E, Kirchner C, Eickmeyer C, Winde G, Henzler D, K\u00f6hler T (2021) Profound decrease of liver maximum function capacity test of isoflurane sedated patients: a report of three cases. Clin Case Rep 9:e04862","journal-title":"Clin Case Rep"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10877-017-0097-9","volume":"32","author":"R Farrell","year":"2018","unstructured":"Farrell R, Oomen G, Carey P (2018) A technical review of the history, development and performance of the anaesthetic conserving device \u201cAnaConDa\u201d for delivering volatile anaesthetic in intensive and post-operative critical care. J Clin Monit Comput 32:595\u2013604","journal-title":"J Clin Monit Comput"},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00134-012-2708-8","volume":"38","author":"J Bosel","year":"2012","unstructured":"Bosel J, Purrucker JC, Nowak F, Renzland J, Schiller P, Perez EB, Poli S, Brunn B, Hacke W, Steiner T (2012) Volatile isoflurane sedation in cerebrovascular intensive care patients using AnaConDa((R)): effects on cerebral oxygenation, circulation, and pressure. Intensive Care Med 38:1955\u20131964","journal-title":"Intensive Care Med"},{"key":"617_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S2213-2600(21)00323-4","volume":"9","author":"A Meiser","year":"2021","unstructured":"Meiser A, Volk T, Wallenborn J, Guenther U, Becher T, Bracht H, Schwarzkopf K, Knafelj R, Faltlhauser A, Thal SC, Soukup J, Kellner P, Druner M, Vogelsang H, Bellgardt M, Sackey P, Sedaconda study group (2021) Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. Lancet Respir Med 9:1231\u20131240","journal-title":"Lancet Respir Med"},{"key":"617_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453\u20131457","journal-title":"Lancet"},{"key":"617_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810","journal-title":"JAMA"},{"key":"617_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative S (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 4:e297","journal-title":"PLoS Med"},{"key":"617_CR15","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/biomedicines10102340","volume":"10","author":"J Praxenthaler","year":"2022","unstructured":"Praxenthaler J, Schwier E, Altmann S, Kirchner C, Bialas J, Henzler D, Kohler T (2022) Immunomodulation by hemoadsorption-changes in hepatic biotransformation capacity in sepsis and septic shock: a prospective study. Biomedicines 10:2340","journal-title":"Biomedicines"},{"key":"617_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/00031305.1991.10475767","volume":"45","author":"RA McLean","year":"1991","unstructured":"McLean RA, Sanders WL, Stroup WW (1991) A unified approach to mixed linear models. Am Stat 45:54\u201364","journal-title":"Am Stat"},{"key":"617_CR17","volume-title":"Designing experiments and analyzing data. A model comparison perspective","author":"SE Maxwell","year":"2004","unstructured":"Maxwell SE, Delaney HD (2004) Designing experiments and analyzing data. A model comparison perspective. Lawrence Erlbaum Associates, Mahwah"},{"key":"617_CR18","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1124\/dmd.111.038679","volume":"39","author":"LJ Dickmann","year":"2011","unstructured":"Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415\u20131422","journal-title":"Drug Metab Dispos"},{"key":"617_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cpt.2432","volume":"112","author":"AD Dunvald","year":"2022","unstructured":"Dunvald AD, Jarvinen E, Mortensen C, Stage TB (2022) Clinical and molecular perspectives on inflammation-mediated regulation of drug metabolism and transport. Clin Pharmacol Ther 112:277\u2013290","journal-title":"Clin Pharmacol Ther"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/biomedicines10102340","volume":"10","author":"J Praxenthaler","year":"2022","unstructured":"Praxenthaler J, Schwier E, Altmann S, Kirchner C, Bialas J, Henzler D, K\u00f6hler T (2022) Immunomodulation by hemoadsorption-changes in hepatic biotransformation capacity in sepsis and septic shock: a prospective study. Biomedicines 10:2340","journal-title":"Biomedicines"},{"key":"617_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fphar.2010.00129","volume":"1","author":"K Klein","year":"2010","unstructured":"Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM (2010) Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 1:129","journal-title":"Front Pharmacol"},{"key":"617_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1477-2574.2009.00151.x","volume":"12","author":"M Stockmann","year":"2010","unstructured":"Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P (2010) The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 12:139\u2013146","journal-title":"HPB (Oxford)"},{"key":"617_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/gut.52.1.134","volume":"52","author":"F Botta","year":"2003","unstructured":"Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R (2003) MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 52:134\u2013139","journal-title":"Gut"},{"key":"617_CR24","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/aa820b","volume":"12","author":"TM Rubin","year":"2017","unstructured":"Rubin TM, Heyne K, Luchterhand A, Bednarsch J, Vondran FWR, Polychronidis G, Malinowski M, Nikolic A, Tautenhahn HM, Jara M, W\u00fcnsch T, Stockmann M, Friso Lock J (2017) Kinetic validation of the LiMAx test during 10 000 intravenous. J Breath Res 12:016005","journal-title":"J Breath Res"},{"key":"617_CR25","unstructured":"Humedics (2022) Gebrauchsanweisung \"FLIP 2.0\" Leberfunktionsmessger\u00e4t (FLIP-Messger\u00e4t). In: Editor (ed)^(eds) Book Gebrauchsanweisung \"FLIP 2.0\" Leberfunktionsmessger\u00e4t (FLIP-Messger\u00e4t). City, pp."},{"key":"617_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1523-5378.2005.00357.x","volume":"10","author":"B Riecke","year":"2005","unstructured":"Riecke B, Neuhaus P, Stockmann M (2005) Major influence of oxygen supply on 13CO2:12CO2 ratio measurement by nondispersive isotope-selective infrared spectroscopy. Helicobacter 10:620\u2013622","journal-title":"Helicobacter"},{"key":"617_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/CH-179229","volume":"67","author":"D Henzler","year":"2017","unstructured":"Henzler D, Scheffler M, Westheider A, K\u00f6hler T (2017) Microcirculation measurements: barriers for use in clinical routine. Clin Hemorheol Microcirc 67:505\u2013509","journal-title":"Clin Hemorheol Microcirc"},{"key":"617_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1213\/ANE.0b013e31827b27b0","volume":"116","author":"SD Edmands","year":"2013","unstructured":"Edmands SD, Ladow E, Hall AC (2013) Microarray analyses of genes regulated by isoflurane anesthesia in vivo: a novel approach to identifying potential preconditioning mechanisms. Anesth Analg 116:589\u2013595","journal-title":"Anesth Analg"},{"key":"617_CR29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/01.CIR.74.5.1124","volume":"74","author":"CE Murry","year":"1986","unstructured":"Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124\u20131136","journal-title":"Circulation"},{"key":"617_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1213\/ANE.0000000000002385","volume":"125","author":"Z Rao","year":"2017","unstructured":"Rao Z, Pan X, Zhang H, Sun J, Li J, Lu T, Gao M, Liu S, Yu D, Ding Z (2017) Isoflurane preconditioning alleviated murine liver ischemia and reperfusion injury by restoring AMPK\/mTOR-mediated autophagy. Anesth Analg 125:1355\u20131363","journal-title":"Anesth Analg"},{"key":"617_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/EJA.0b013e3283212cbb","volume":"26","author":"S Hieber","year":"2009","unstructured":"Hieber S, Huhn R, Hollmann MW, Weber NC, Preckel B (2009) Hypoxia-inducible factor 1 and related gene products in anaesthetic-induced preconditioning. Eur J Anaesthesiol 26:201\u2013206","journal-title":"Eur J Anaesthesiol"},{"key":"617_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721\u2013732","journal-title":"Nat Rev Cancer"},{"key":"617_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nri.2016.70","volume":"16","author":"LA O'Neill","year":"2016","unstructured":"O\u2019Neill LA, Kishton RJ, Rathmell J (2016) A guide to immunometabolism for immunologists. Nat Rev Immunol 16:553\u2013565","journal-title":"Nat Rev Immunol"},{"key":"617_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1213\/01.ane.0000226094.94877.98","volume":"103","author":"C Wang","year":"2006","unstructured":"Wang C, Weihrauch D, Schwabe DA, Bienengraeber M, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS (2006) Extracellular signal-regulated kinases trigger isoflurane preconditioning concomitant with upregulation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in rats. Anesth Analg 103:281\u2013288","journal-title":"Anesth Analg"},{"key":"617_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/cvr\/cvn016","volume":"78","author":"J Feng","year":"2008","unstructured":"Feng J, Lucchinetti E, Fischer G, Zhu M, Zaugg K, Schaub MC, Zaugg M (2008) Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB. Cardiovasc Res 78:98\u2013107","journal-title":"Cardiovasc Res"},{"key":"617_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ALN.0b013e318164cab1","volume":"108","author":"J Raphael","year":"2008","unstructured":"Raphael J, Zuo Z, Abedat S, Beeri R, Gozal Y (2008) Isoflurane preconditioning decreases myocardial infarction in rabbits via up-regulation of hypoxia inducible factor 1 that is mediated by mammalian target of rapamycin. Anesthesiology 108:415\u2013425","journal-title":"Anesthesiology"},{"key":"617_CR37","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00018-003-2370-y","volume":"60","author":"CP Bracken","year":"2003","unstructured":"Bracken CP, Whitelaw ML, Peet DJ (2003) The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60:1376\u20131393","journal-title":"Cell Mol Life Sci"},{"key":"617_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-54620-8","volume-title":"Stryer Biochemie","author":"JM Berg","year":"2018","unstructured":"Berg JM, Tymoczko JL, Gatto GJ Jr, Stryer L (2018) Stryer Biochemie. Springer Spektrum, Berlin"},{"key":"617_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cpt.444","volume":"100","author":"J Matthaei","year":"2016","unstructured":"Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Moller S, Halekoh U, Hofmann U, Schwab M, Kerb R, Brockmoller J (2016) Heritability of caffeine metabolism: environmental effects masking genetic effects on CYP1A2 activity but not on NAT2. Clin Pharmacol Ther 100:606\u2013616","journal-title":"Clin Pharmacol Ther"},{"key":"617_CR40","doi-asserted-by":"publisher","first-page":"14558","DOI":"10.1074\/jbc.M109.076323","volume":"285","author":"MA Schults","year":"2010","unstructured":"Schults MA, Timmermans L, Godschalk RW, Theys J, Wouters BG, van Schooten FJ, Chiu RK (2010) Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem 285:14558\u201314564","journal-title":"J Biol Chem"},{"key":"617_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/humu.21132","volume":"31","author":"LF Jorge-Nebert","year":"2010","unstructured":"Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, McGarvey ST, Deka R, Nebert DW (2010) Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 31:27\u201340","journal-title":"Hum Mutat"},{"key":"617_CR42","first-page":"339","volume":"18","author":"R Wu","year":"2006","unstructured":"Wu R, Cui X, Dong W, Zhou M, Simms HH, Wang P (2006) Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines. Int J Mol Med 18:339\u2013346","journal-title":"Int J Mol Med"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-024-00617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-024-00617-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-024-00617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T16:06:54Z","timestamp":1712592414000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-024-00617-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s40635-024-00617-8","relation":{},"ISSN":["2197-425X"],"issn-type":[{"type":"electronic","value":"2197-425X"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics committee of the Ruhr-University Bochum, Germany (file number: 2020-661, dated 28 Aug 2020). The patient or substitute decision-maker was informed about the study by an investigator, and written informed consent was obtained for all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TK received lecture fees from Sedana Medical Germany. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}